Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Aug;152(8):2925-6.
doi: 10.1210/en.2011-1385.

What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract

David A D'Alessio  1
Affiliations
Comment

What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract

David A D'Alessio. Endocrinology. 2011 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Baggio LL, Drucker DJ. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157 - PubMed
    1. Lovshin JA, Drucker DJ. 2009. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262–269 - PubMed
    1. Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. 2010. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 73:189–196 - PMC - PubMed
    1. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. 2003. Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1-(9–36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772–1779 - PubMed
    1. Amori RE, Lau J, Pittas AG. 2007. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194–206 - PubMed

Publication types

MeSH terms